Placebo (NNC6019-0001)

DRUG3 trials

Sponsors

Novo Nordisk A/S

Conditions

The present study will include a population of patients with established ATTR CM.Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Phase 2

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

CompletedNCT05442047

Novo Nordisk A/STransthyretin Amyloid Cardiomyopathy (ATTR CM)

Start: 2022-08-02End: 2025-05-13Updated: 2026-02-17

Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy (ATTR CM).

CompletedCTIS2023-506824-96-00

Novo Nordisk A/SThe present study will include a population of patients with established ATTR CM.

Start: 2023-05-23End: 2025-04-30Target: 61Updated: 2025-04-11

Phase 3

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

RecruitingNCT07207811

Novo Nordisk A/STransthyretin Amyloid Cardiomyopathy (ATTR CM)

Start: 2025-10-02End: 2029-06-29Target: 1280Updated: 2026-03-19

Related Papers

Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.

2025-11-101 citations

PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study

Amyloid2024-10-2929 citations